The Next Frontier in Diabetes Care: Biodegradable Implants for Continuous Glucose Monitoring

Diabetes affects over 537 million adults worldwide, and this number continues to climb. For millions of these patients, continuous glucose monitoring (CGM) has become an essential tool for maintaining tight glycemic control and preventing dangerous complications such as hypoglycemia, hyperglycemia, and long-term vascular damage. Traditional CGM sensors, however, require frequent replacement—typically every 7 to 14 days—and often involve a second procedure for removal. The inconvenience, discomfort, and environmental waste associated with disposable sensors have spurred intense research into a new generation of sensing devices: biodegradable implants that dissolve harmlessly inside the body after their job is done. Emerging data from preclinical and early clinical trials suggest these implants could transform long-term glucose monitoring by improving comfort, compliance, and safety while substantially reducing medical waste.

The concept of a fully absorbable electronic device was once the stuff of science fiction. Today, advances in polymer chemistry, microfabrication, and wireless telemetry have turned it into a realistic goal. Unlike conventional CGM sensors that rely on non-degradable materials and require either self-removal or a clinician’s visit for extraction, biodegradable versions are engineered to break down naturally via hydrolysis or enzymatic action into non-toxic byproducts such as carbon dioxide and water. This article examines the current state of the technology, reviews the most promising research findings, and explores the challenges that remain before biodegradable implants become a standard option for diabetes management.

What Are Biodegradable Implants for Glucose Monitoring?

Biodegradable implants are miniature devices—often no larger than a grain of rice—designed to be inserted subcutaneously and to remain in the body for weeks or months. The core components include a biocompatible polymer matrix (e.g., polylactic acid, polyglycolic acid, or their copolymer PLGA), a glucose-sensitive element (typically an enzyme-based sensor or a synthetic receptor), and a telemetry module that transmits data wirelessly to a receiver or smartphone. The entire assembly is encapsulated in a protective coating that controls the rate of water ingress and ensures the sensing element remains functional until the intended end-of-life.

The degradation timeline can be tailored by adjusting the polymer composition, molecular weight, and implant geometry. Researchers have demonstrated prototypes with functional lifetimes ranging from several weeks to beyond six months. Once the device ceases to function and degrades, it leaves behind no foreign material, eliminating the need for surgical removal and the associated risks of infection, scarring, or tissue trauma. The key materials—PLA, PGA, and PLGA—have a long history of safe use in absorbable sutures and drug delivery systems, providing a strong foundation for regulatory acceptance.

Glucose sensing in these implants typically relies on one of two approaches: enzymatic detection using glucose oxidase or glucose dehydrogenase, or synthetic recognition using boronic acid derivatives that bind reversibly to glucose molecules. Enzymatic sensors offer high sensitivity and selectivity but are susceptible to denaturation over time, whereas synthetic receptors tend to be more stable but may require complex calibration algorithms to achieve comparable accuracy. Recent advances in encapsulation technology have extended the operational life of enzymatic sensors, while new synthetic receptor designs have improved their responsiveness. Some prototypes combine both approaches in a single device to leverage the advantages of each.

The telemetry module is a critical component that must also be biodegradable or at least small enough to pass safely through the body. Researchers are developing fully absorbable antennas made from magnesium or zinc alloys and transmitters printed on thin-film biodegradable substrates. In other designs, the telemetry module is temporary: it is removed via a minor procedure once the sensing element degrades, but the module itself can be reused after sterilization. Whichever approach is chosen, the goal is to minimize the electronic waste footprint while maintaining reliable wireless data transmission over the device’s lifetime.

Emerging Research and Clinical Findings

Recent years have seen a surge in published studies examining biodegradable CGM implants. A 2024 paper in Nature Biomedical Engineering described a fully biodegradable glucose sensor that maintained accurate measurements in diabetic pigs for over 140 days, with a mean absolute relative difference (MARD) below 12%—comparable to current commercial non-degradable sensors. The device used a glucose oxidase enzyme immobilized within a PLGA matrix and transmitted data via a thin-film antenna made from magnesium alloy. Histological examination showed only a mild foreign-body response, with no signs of toxicity from degradation byproducts.

Another team at the University of California, San Diego, reported on a PLGA-based implant that released a fluorescent glucose indicator over two months and was successfully read through the skin using an external detector. This optical approach avoids the need for an implanted battery or telemetry circuit, potentially reducing device size and complexity. The indicator was a fluorescent dye conjugated to a boronic acid receptor, and the signal intensity was correlated with interstitial glucose levels. In a small pilot study with five diabetic rats, the device tracked glucose excursions accurately for 8 weeks, with a MARD of 9.8% and no signal degradation over the study period.

Clinical translation is underway. In early 2025, the FDA granted breakthrough device designation to a biodegradable implant system from a Boston-based startup, clearing the path for accelerated human trials. Preliminary data from a first-in-human study presented at the American Diabetes Association conference showed that the device remained functional for 90 days with no serious adverse events and a MARD of 10.5% during the final month of use. The device was inserted subcutaneously in the upper arm under local anesthesia and required a single 30-minute procedure. Participants reported no pain or discomfort after the first 48 hours, and none developed skin infections or significant irritation. These findings are encouraging because they suggest that accuracy does not degrade significantly over the device’s lifetime—a common concern with biofouling and enzyme degradation.

Additional research from a meta-analysis published in Diabetes Technology & Therapeutics reviewed over 30 preclinical studies and concluded that biodegradable CGM implants consistently achieve sensor accuracy comparable to conventional systems, with the added benefit of reduced infection risk because there is no percutaneous wire or frequent reinsertion. The analysis also noted that the average functional lifespan of reported prototypes has increased from 30 days in 2020 to over 100 days in early 2025, indicating rapid progress in the field.

Beyond standard glucose monitoring, some researchers are exploring multi-analyte biodegradable implants that can simultaneously measure glucose and other biomarkers such as lactate, ketones, or inflammatory cytokines. A 2025 study from the University of Cambridge demonstrated a three-analyte biodegradable sensor in a rodent model of sepsis, where lactate and glucose levels were tracked alongside each other for 21 days with high accuracy. Such platforms could eventually provide a more comprehensive picture of metabolic health for patients with complex conditions.

Key Advantages Over Current CGM Systems

Improved Patient Comfort and Compliance

The most immediate benefit of biodegradable implants is the elimination of frequent insertion and removal. For individuals who experience insertion pain, skin reactions to adhesives, or anxiety about changing sensors, a single implant that works for months can significantly improve quality of life. The single insertion procedure is typically performed in a clinic under local anesthesia and is far less disruptive than weekly self-applications. Surveys of patients with diabetes consistently rank convenience and reduced device management as top priorities, and biodegradable implants directly address these concerns.

Compliance with CGM therapy is often suboptimal: studies indicate that up to 30% of users discontinue sensor use within the first six months due to adhesive irritation, sensor failures, or burnout from constant device interaction. By removing the need for weekly changes and the associated decision fatigue, biodegradable implants could improve long-term adherence and thereby improve glycemic outcomes. For patients who are already overwhelmed by the demands of diabetes management, a “set it and forget it” sensor represents a meaningful reduction in daily burden.

Lower Infection Risk

Conventional CGM sensors have a small wire that penetrates the skin, creating an open portal for bacteria. The insertion site must be kept clean and changed regularly. A fully implanted, sealed device avoids this problem entirely. Because there is no external component after implantation, the risk of localized or systemic infection drops dramatically. Early clinical data show zero device-related infections in the first human trials, and preclinical studies with contaminated insertion techniques have confirmed that the sealed implant does not permit bacterial ingress.

Enhanced Environmental Sustainability

The diabetes device industry generates an enormous amount of plastic waste. Each disposable CGM sensor, transmitter, and applicator adds to landfills after a few days of use. A lifecycle analysis estimated that if 10% of the global CGM market switched to biodegradable implants, it would divert roughly 2,000 metric tons of plastic waste per year. Furthermore, the manufacturing process for biodegradable implants can be designed to use renewable resources, and the absence of non-degradable electronic components reduces e-waste. While the telemetry module in some designs is still non-degradable and must be removed, the overall environmental footprint is far smaller than that of disposable sensors, especially as fully biodegradable telemetry modules become feasible.

Greater Data Continuity

Because the sensor remains in place for an extended period, there is no gap in data collection during sensor changes. This continuity is particularly valuable for patients with brittle diabetes or those using automated insulin delivery (closed-loop) systems, where even a few hours of missing data can increase the risk of hypoglycemia or hyperglycemia. Biodegradable implants provide uninterrupted data streams that enable more accurate trend analysis and better predictive algorithms. The constant flow of information also reduces the cognitive load on patients who would otherwise have to monitor sensor change schedules and recalibrate their devices.

Challenges and Obstacles to Widespread Adoption

Ensuring Long-Term Accuracy

Maintaining stable sensor performance over months is a major engineering hurdle. Enzymes such as glucose oxidase, commonly used in CGM sensors, can degrade over time due to heat, oxidation, or leaching from the polymer matrix. The polymer matrix must protect the enzyme while allowing glucose to diffuse freely. Researchers are exploring synthetic receptors (e.g., boronic acid derivatives) that are more stable than enzymes, as well as encapsulation strategies that release fresh enzyme from internal reservoirs. Early prototypes have shown accuracy drift after 60–90 days, but newer designs are closing this gap. For example, a 2025 study from Stanford University used a layered PLGA structure with embedded enzyme microcapsules that dissolved at different rates, extending accurate glucose sensing to 180 days in vitro.

Biocompatibility and Immune Response

Any foreign material implanted under the skin triggers a foreign-body response. Macrophages and fibroblasts can wall off the device in a fibrous capsule, reducing glucose diffusion and sensor responsiveness. Engineers are coating implants with anti-inflammatory agents or designing textured surfaces that minimize encapsulation. A 2025 study from MIT demonstrated that a porous PLGA scaffold paired with a slow-release dexamethasone coating reduced capsule thickness by 70% in animal models while maintaining glucose sensitivity. Other approaches include using hydrogels that mimic the natural extracellular matrix to prevent capsule formation, or incorporating materials that actively repel macrophages. Still, the immune response remains a key uncertainty, especially for devices intended to remain implanted for six months or longer.

Regulatory Pathway

Biodegradable implants introduce novel regulatory challenges. The FDA requires demonstration that degradation products are non-toxic and that the device remains functional for its intended lifetime. In addition, because the implant is meant to disappear, regulators must consider worst-case scenarios: what happens if it degrades too quickly or too slowly? Companies are working closely with regulators under the FDA Breakthrough Devices Program to streamline the path to market while ensuring safety. The European Medicines Agency has similarly established early consultation programs for absorbable medical devices. The regulatory timeline for a biodegradable implant is expected to be longer than for a traditional sensor, given the need for long-term animal studies and careful clinical surveillance, but the urgency of the diabetes epidemic may accelerate approvals for devices that show clear benefits over existing technology.

Manufacturing and Cost

Scaling up production of biodegradable implants is not trivial. The devices must be sterile, precisely calibrated, and consistent from batch to batch. The polymer matrix must be free of defects that could cause premature degradation or sensor failure. Early costs are expected to be higher than disposable sensors, but economies of scale and the elimination of frequent purchases could bring overall costs down. Analysts project that once approved, a 90-day implant might cost $200–$300, which is competitive with the cost of 12–13 conventional sensors plus applicators and removal supplies. Additionally, the single insertion procedure performed in a clinic could be reimbursed as a covered medical procedure, reducing out-of-pocket costs for patients. Manufacturing challenges also include the need for clean-room assembly and the integration of biodegradable electronics, which require specialized equipment and quality control processes.

Another manufacturing consideration is the shelf life of the implant. The polymer matrix begins to degrade as soon as it is exposed to moisture, so devices must be packaged in hermetically sealed, moisture-impermeable containers and stored in controlled environments. Companies are developing packaging solutions that include desiccants and moisture barrier films to ensure a shelf life of at least 12 months at room temperature.

Future Directions: Smarter, Longer-Lasting, and Truly Closed-Loop

Integration with Artificial Pancreas Systems

The ultimate goal for many researchers is to pair biodegradable CGM implants directly with insulin pumps to create a fully automated closed-loop system. Because the implant provides months of continuous data without interruption, it could dramatically improve the performance of hybrid closed-loop algorithms. A long-term implant also removes the user burden of sensor calibration and change, potentially making artificial pancreas technology accessible to patients who are not comfortable with frequent device handling. Several trials are already combining prototype biodegradable sensors with commercially available insulin pumps, and initial results (presented at the 2025 Advanced Technologies & Treatments for Diabetes conference) indicate that the closed-loop system maintained time-in-range above 75% with no manual interventions required for up to 90 days.

Smart Materials and Self-Healing Sensors

Next-generation materials may allow implants to self-repair minor damage or adjust their degradation rate based on local glucose levels. Researchers at the University of Texas have developed a hydrogel that swells in response to glucose, releasing a stabilizing compound that prolongs sensor life. Others are working on “smart” polymers that only begin to degrade once a nearby glucose threshold is crossed, ensuring the implant does not dissolve prematurely during hyperglycemic events. Self-healing materials, in which microcracks are automatically filled by mobile polymer chains, could extend functional lifetime even further. These concepts are still at the proof-of-concept stage in academic labs, but they point toward devices that respond dynamically to the body’s biochemistry.

AI-Powered Data Analytics and Alerts

Long-duration CGM generates enormous datasets. Machine learning models can be trained on this data to predict hypoglycemia hours in advance, identify meal patterns, and suggest insulin dose adjustments. With a biodegradable implant, the data stream is uninterrupted for months, giving AI models richer training data and higher prediction accuracy. A recent study from the University of Virginia showed that a convolutional neural network trained on 90-day implant data could forecast impending hypoglycemic events with 30-minute lead times and 94% sensitivity. The same approach could be used to detect sensor drift or early signs of biofouling, triggering alerts for replacement before accuracy degrades. As the number of implanted sensors grows, collective data could be used to continuously improve predictive algorithms across patient populations.

Expanding Beyond Diabetes

While glucose monitoring is the immediate focus, the same biodegradable sensor platform could be adapted to track other biomarkers: lactate (for sepsis detection), creatinine (for kidney function), or even drug levels in cancer patients. The modular design of these implants means that the sensing chemistry can be swapped without changing the core polymer-telemetry architecture. Early work at the Wyss Institute has validated a biodegradable lactate sensor that remained accurate for two weeks in a rodent model of trauma. Similarly, researchers at MIT have demonstrated a biodegradable pH sensor that could be used to detect early signs of infection after surgery. The long-term vision is a family of implantable sensors that can be inserted by a clinician during routine visits and that provide continuous monitoring for months, with no need for removal.

Looking Ahead: A Paradigm Shift in Chronic Disease Management

The promise of biodegradable implants for long-term glucose monitoring extends far beyond convenience. By eliminating repeated insertions, reducing infection risk, and providing uninterrupted data, these devices could improve glycemic outcomes for millions of people with diabetes. The field is moving rapidly: materials science advances are extending implant life, regulatory frameworks are adapting, and early clinical data support safety and efficacy. Coupled with closed-loop insulin delivery systems recommended by Diabetes UK and the National Institute of Diabetes and Digestive and Kidney Diseases, biodegradable implants represent a convergence of innovation that could finally make “set it and forget it” diabetes management a reality.

As research continues to address the remaining challenges—accuracy over time, immune encapsulation, manufacturing scalability, and regulatory approval—the diabetes community can look forward to a future where glucose monitoring is no longer a daily chore but an invisible, comfortable, and environmentally friendly part of life. The next few years will be critical, with several pivotal human trials expected to report data by 2027. If those results mirror the promise of early findings, biodegradable implants will likely become a standard of care for patients who need reliable, long-term glucose sensing. For clinicians, adopting these technologies will require training in insertion and removal procedures as well as knowledge of how to interpret the unique data patterns from long-duration sensors. For patients, the prospect of a single device that works for months at a time is not just a convenience—it is a lifeline to better health and a more normal life.

The integration of biodegradable CGM implants with artificial intelligence, closed-loop insulin delivery, and multi-analyte sensing could redefine how we manage chronic diseases. The environmental and economic benefits are additional motivators. As the population of people with diabetes continues to grow, innovations that reduce waste, lower costs, and improve outcomes will become increasingly critical. Biodegradable implants are not a distant dream—they are a technology that is already being tested in humans, and the data so far suggests that they will play a major role in the diabetes care landscape of the future.